{"entity":{"id":"nct06569420","kind":"trial","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","aka":[],"tldr":"A phase 3 trial of an investigational treatment in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.","summary":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC is a phase 3 interventional study registered as NCT06569420 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 275 participants enrolled, started 2021-12-31 and due to reach its primary completion in 2025-07-31.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06569420","url":"https://clinicaltrials.gov/study/NCT06569420"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","alk-positive-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["shanghai-fosun-pharmaceutical-industrial-development"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06569420","phase":"3","setting":"A Randomized, Multicenter, Phase III Open-label Study: Efficacy and Safety of Comparing SAF-189s With Crizotinib in First-line Anaplastic Lymphoma Kinase-positive Advanced and Metastatic NSCLC","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","participation":[{"nct":"NCT06569420","source":"https://clinicaltrials.gov/study/NCT06569420","fetchedAt":"2026-10-07T16:54:48.431Z","studySha256":"06ae7b5e73ebf6c152f292f6c012d6d9b88ce25a12ada878cafbecf8eef8229f","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2024-08-26","leadSponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":275,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2021-12-31","startedType":"actual","enrolled":275,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06569420/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/"}]}}